Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: What the TROPHAMET Trial Adds to First-Line Care
Highlights
The TROPHAMET phase 1/2 nonrandomized clinical trial evaluated avelumab, a PD-L1 inhibitor, combined with methotrexate as first-line therapy for low-risk gestational trophoblastic tumors (GTT).
Among 26 assessable patients, serum hCG normalized in 96.2%, with no relapses observed after a median follow-up of 41 months.
The regimen was generally well tolerated; one dose-limiting toxicity occurred, and no grade 4 or higher adverse events were reported.
Fertility was preserved in most patients with pregnancy intent: 13 of 14 achieved pregnancy.
Study background and clinical need
Gestational trophoblastic tumors encompass a spectrum of pregnancy-related neoplasms arising from trophoblastic tissue, including malignant forms such as invasive mole and choriocarcinoma. For low-risk disease, defined here by a FIGO score of 6 or lower, single-agent chemotherapy is the standard first-line approach and is curative in most patients. However, cure rates are not perfect, and a subset of patients experiences resistance, prolonged treatment, or the need for escalation to multi-agent chemotherapy. This is clinically important because prolonged exposure to chemotherapy can increase toxicity, delay hCG normalization, and complicate future fertility planning.
The biological rationale for immune checkpoint inhibition in GTT is strong. Trophoblastic tumors often express programmed death-ligand 1 (PD-L1), which helps tumor cells evade immune surveillance. Avelumab, a monoclonal antibody targeting PD-L1, has already shown activity in chemotherapy-resistant GTT. TROPHAMET asked a clinically relevant question: could adding avelumab earlier, at the start of therapy, improve outcomes while keeping toxicity acceptable?
Study design
TROPHAMET (Avelumab and Methotrexate in Low-Risk Gestational Trophoblastic Neoplasias as First-Line Treatment) was a multicenter, phase 1/2 nonrandomized clinical trial conducted at academic referral centers. Patients had low-risk GTT with FIGO scores of 6 or lower and were treated between April 14, 2020, and December 5, 2023. Data analysis was performed from December 20, 2024, to July 3, 2025.
The intervention consisted of avelumab, 800 mg intravenously on day 1, plus methotrexate, 1 mg/kg intramuscularly on days 1, 3, 5, and 7, alternating with oral folinic acid in 2-week cycles until serum human chorionic gonadotropin (hCG) normalized. Patients then received 3 consolidation cycles. In phase 1, the primary endpoint was dose-limiting toxic effects (DLTs). In phase 2, the main endpoint was the rate of hCG normalization that allowed treatment discontinuation.
Because this was a single-arm study, there was no randomized control group receiving methotrexate alone. As a result, interpretation relies on historical benchmarks rather than direct comparative evidence.
Key findings
Twenty-seven female patients received treatment, and 26 were assessable for efficacy. Median age was 35 years, ranging from 20 to 50 years. The cohort included a broad spread of disease burden within the low-risk category: 31% had FIGO scores of 1 to 2, another 31% had scores of 3 to 4, and 38% had scores of 5 to 6. This matters because outcomes and risk of methotrexate resistance tend to worsen as the FIGO score rises, even within the low-risk group.
The combination showed a very high rate of disease control. hCG normalized successfully in 96.2% of evaluable patients, with a 90% confidence interval of 85.9% to 97.9%. In practical terms, this means most patients achieved the biochemical remission needed to stop treatment, and the result compares favorably with the approximate 70% cure rate often cited for standard single-agent chemotherapy in low-risk GTT. However, because the study was nonrandomized, this comparison should be interpreted cautiously: cross-trial differences in patient mix, monitoring, and treatment rules can inflate apparent benefit.
Durability of response was encouraging. After a median follow-up of 41 months, no relapses were observed. For a disease where most recurrences occur relatively early after treatment, this is a reassuring signal, though longer follow-up and larger cohorts remain important for confirming long-term remission rates.
Toxicity was manageable. One DLT occurred, namely grade 3 sepsis related to the central venous catheter. Immune-related and treatment-related adverse events of grade 2 or higher occurred in 6 patients (22%). These events fully resolved except for one case of grade 2 dysthyroidism, a thyroid dysfunction consistent with immune checkpoint blockade. Importantly, no grade 4 or higher events were reported. Overall, the safety profile suggests that adding avelumab did not produce a marked toxicity burden in this small trial, although uncommon immune-mediated toxicities could emerge in larger populations.
Fertility outcomes were particularly noteworthy. Among patients with childbearing potential and pregnancy intention, 13 of 14 achieved pregnancy (93%). For patients treated for trophoblastic tumors, preservation of reproductive potential is a major clinical endpoint, especially because many are of reproductive age and may strongly prioritize future fertility. These findings support the possibility that the regimen can achieve high cure rates without compromising reproductive outcomes.
Expert commentary
The TROPHAMET results fit into a growing therapeutic shift in gestational trophoblastic neoplasia from purely cytotoxic therapy toward biologically informed treatment. In a disease with generally high curability, the bar for adopting a new first-line regimen is appropriately high. Any novel strategy must show not only disease control, but also minimal long-term toxicity, fertility preservation, and a clear rationale for use. TROPHAMET provides an encouraging proof-of-concept, especially for patients at the upper end of the low-risk spectrum who are more likely to fail methotrexate alone.
Still, important limitations remain. First, the study was nonrandomized and small, so efficacy estimates are vulnerable to selection bias and uncertainty around external comparators. Second, the trial used a biochemical endpoint, hCG normalization, which is appropriate in this disease but may not capture all clinically meaningful differences versus standard therapy, such as time to remission, cumulative methotrexate exposure, cost, or patient-reported quality of life. Third, the population came from academic referral centers, which may limit generalizability to broader practice settings. Finally, the incremental value of adding avelumab over methotrexate alone cannot be determined without a randomized comparator.
From a mechanistic perspective, the approach is attractive. Methotrexate remains an established antimetabolite in low-risk GTT, while avelumab may counteract the immunologic tolerance that trophoblastic tumors exploit. The combination could theoretically improve initial eradication of residual disease, reduce the emergence of resistance, and shorten treatment courses. Whether this theoretical benefit translates into a meaningful improvement over optimized single-agent chemotherapy needs confirmatory trials.
Clinical implications
For clinicians, the most important practical message is that avelumab plus methotrexate appears feasible and active, with reassuring short- to medium-term safety and preserved fertility in this early-phase study. It does not yet replace methotrexate-based standards of care, but it may represent a promising strategy for patients at greater risk of chemoresistance, especially those with FIGO scores closer to 6. If future randomized studies confirm superiority or noninferiority with added benefits such as fewer relapses or less need for salvage therapy, this regimen could become a meaningful first-line option.
Conclusion
TROPHAMET suggests that combining the PD-L1 inhibitor avelumab with methotrexate can produce very high remission rates in low-risk gestational trophoblastic tumors, with manageable toxicity, durable responses, and high pregnancy rates after treatment. The findings are promising, but they remain hypothesis-generating until validated in comparative trials. For now, the study strengthens the case for immune-chemotherapy combinations in trophoblastic disease and highlights the importance of balancing cure, safety, and fertility preservation.
Funding and clinicaltrials.gov
Trial registration: ClinicalTrials.gov Identifier NCT04396223.
Publication: You B, Lotz JP, Descargues P, Joly F, De La Motte Rouge T, Lebreton C, Gladieff L, Follana P, Jamelot M, Massardier J, Hajri T, Msika A, Alves-Ferreira M, Bin S, Langlois-Jacques C, Subtil F, Roux A, Desauw C, Provansal M, Schwiertz V, Golfier F, Bolze PA. Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial. JAMA oncology. 2026-06-11. PMID: 42275082.
References
1. You B, Lotz JP, Descargues P, et al. Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial. JAMA oncology. 2026-06-11. PMID: 42275082.
2. Ngan HYS, Seckl MJ, Berkowitz RS, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. Int J Gynaecol Obstet. 2021;155 Suppl 1:86-93.
3. Lurain JR. Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasia. Am J Obstet Gynecol. 2011;204(1):11-18.
4. Bolze PA, Rousset-Jablonski C, Nguyen D, et al. Activity of avelumab in chemoresistant gestational trophoblastic neoplasia. [PubMed-indexed clinical evidence supporting immune checkpoint blockade in GTT].
AI image prompt
Modern clinical research illustration showing a female oncology patient and a gynecologic oncologist reviewing hCG test results and treatment charts, with subtle molecular immune checkpoint graphics and a microscopic trophoblastic cell background, clean medical style, high realism, blue-white hospital palette, professional journal thumbnail composition.
